Professional Documents
Culture Documents
Growth Rate (AGR) of 1.49%. GlobalData epidemiologists also forecast that the diagnosed
prevalent cases of COPD will increase from 18,920,845 cases in 2013 to 21,789,454 cases
in 2023 at an AGR of 1.52%. In the 8MM in 2013, 16.41% of the diagnosed prevalent cases
of COPD were in GOLD Stage I, 24.66% were in GOLD Stage II, 29.09% were in GOLD Stage
III, and 29.84% were in GOLD Stage IV. GlobalData epidemiologists estimated that
18,065,499 of the diagnosed prevalent cases of COPD in 2013 would have survived to the
end of the year.
patients. GlobalData epidemiologists also describe in detail the sources and methodology
that were used in the forecast, thereby ensuring transparency of the forecasting process.
Scope
- The Chronic Obstructive Pulmonary Disease (COPD) EpiCast Report provides an overview
of the risk factors, comorbidities, and global trends for COPD in the eight major markets
(8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year
epidemiological forecast of the total prevalent cases of COPD and total diagnosed
prevalent cases of COPD, segmented by age and sex. Additionally it provides
segmentation of diagnosed prevalent cases by severity using the GOLD standard.
- The COPD epidemiology report is written and developed by Masters- and PhD-level
epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing
expert analysis of disease trends in the 8MM.
Table of Contents
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz